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Cadmium (Cd) exposure results in injury to the proximal
tubule characterized by polyuria and proteinuria. Kidney
injury molecule-1 (Kim-1) is a transmembrane glycoprotein
not normally detected in the mature kidney, but is
upregulated and shed into the urine following nephrotoxic
injury. In this study, we determine if Kim-1 might be a useful
early biomarker of Cd nephrotoxicity. Male Sprague–Dawley
rats were given daily injections of Cd for up to 12 weeks.
Weekly urine samples were analyzed for Kim-1, protein,
creatinine, metallothionein, and Clara cell protein CC-16.
Significant levels of Kim-1 were detected in the urine by
6 weeks and continued to increase throughout the
treatment period. This appearance of Kim-1 occurred
4–5 weeks before the onset of proteinuria, and 1–3 weeks
before the appearance of metallothionein and CC-16. Higher
doses of Cd gave rise to higher Kim-1 excretion. Reverse
transcriptase-polymerase chain reaction (RT-PCR) expression
analysis showed that Kim-1 transcript levels were increased
after 6 weeks at the low dose of Cd. Immunohistochemical
analysis showed that Kim-1 was present in proximal tubule
cells of the Cd-treated rats. Our results suggest that Kim-1
may be a useful biomarker of early stages of Cd-induced
proximal tubule injury.
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Cadmium (Cd) is an important industrial and environmental
pollutant that has pleomorphic effects on multiple organ
systems. Depending on the dose, route, and duration of
exposure, Cd can damage various organs including the lung,
liver, kidney, bone, and testis.1–4 In addition, Cd is
teratogenic and carcinogenic.5–7 With the chronic, low-level
patterns of exposure that are common in humans, the kidney
is a primary target of toxicity. Cd causes a generalized
dysfunction of the proximal tubule that is characterized by
polyuria and proteinuria.8–11 Several recent studies have
highlighted the fact that adverse renal effects of Cd may result
from even very low levels of exposure, and that children and
individuals with confounding health conditions may be
especially susceptible.12–15
As a result of its ability to accumulate Cd and its
sensitivity to injury, the kidney is, in effect, a sentinel of Cd
exposure, and much attention has been focused on the
identification of urinary biomarkers of the early stages of Cd
nephrotoxicity.16–21 Some of the biomarkers that have been
used for this purpose include metallothionein,22 b2-micro-
globulin,10 and CC-16.23 Metallothionein is a specific metal
binding protein that plays a role in delivering Cd to the
epithelial cells of the proximal tubule.24–27 The urinary
excretion of metallothionein has been used both as a marker
of Cd exposure and renal injury.20,21,28 b2-Microglobulin and
CC-16 are low-molecular-weight proteins that are present at
low levels in the plasma. Under normal conditions, they are
filtered at the glomerulus and are efficiently reabsorbed by
the proximal tubule.29,30 When the proximal tubule is
injured, however, elevated levels of these proteins begin to
appear in the urine.10,16,23,31 b2-Microglobulin has been
widely utilized in monitoring human populations for early
signs of Cd-induced renal dysfunction.16,19,32,33 Although
CC-16 has not been widely used as a marker of Cd toxicity in
humans, it has been used for this purpose in experimental
studies in rats, where it has been shown to be comparable to
b2-microglobulin as a marker of Cd nephrotoxicity.
34
While these markers have been used to monitor Cd
toxicity in humans and experimental animals, several
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problems remain. For example, the urinary excretion of
metallothionein is a marker of Cd exposure as well as
proximal tubular injury, but identifying the critical level of
urinary metallothionein to indicate the onset of tubular
injury has been problematic.16,19,21,22,28,35,36 Moreover, it is
not totally clear if increases in the urinary excretion of b2-
microglobulin and CC-16 are solely markers of tubular
dysfunction, or are a reflection of the blood levels of the
proteins, which can be influenced by actions of toxicants on
organs other than the kidney.21
Kidney injury molecule-1 (Kim-1), which is also known as
hepatitis A virus cellular receptor 1 (Havcr1),37 is a type I
transmembrane protein that is not detectable in normal
kidney tissue, but is expressed at high levels in de-
differentiated proximal tubule epithelial cells after ischemic
or toxic injury.16,38,39 It has been proposed that Kim-1
functions as a regulator of cell–cell adhesion at a time when
the dedifferentiated regenerating cells of the injured proximal
tubule relocate to denuded patches of the basement
membrane and reform a continuous epithelial layer.40 This
process is associated with the proteolytic cleavage of the
ectodomain of Kim-1 into the urine.40 The Kim-1 ectodo-
main is stable in urine and can be detected in the urine of
humans with acute kidney injury,38 and in a variety of
nephrotoxic models in animals.39,41,42 Kim-1 has been shown
to be a sensitive marker of renal injury induced by cisplatin,
S-(1,1,2,2,-tetrafluoroethyl)-L-cysteine, folic acid,39,42 Hg,43
and cyclosporine.44
The purpose of the present study was to evaluate the possible
utility of Kim-1 as an early urinary biomarker of Cd-induced
renal injury. This study entailed the use of a well-established sub-
chronic model of Cd exposure in rats and a direct comparison
of the Kim-1 results with two other accepted urinary markers of
Cd nephrotoxicity: metallothionein and CC-16.
RESULTS
Effects of Cd on body weight, and urinary and blood
parameters
As can be seen in Figure 1a, Cd-treated (0.6 mg/kg/5 days per
week) animals gained significantly less weight than control
animals over the 12 weeks of treatment. Cd had no effect on
urinary creatinine excretion (Figure 1c). However, after 9–10
weeks, the Cd-treated animals showed a significant increase
in urine volume (Figure 1b) and protein excretion (Figure
1d). The development of polyuria and proteinuria without
significant changes in creatinine excretion is characteristic of
Cd-induced proximal tubule dysfunction.9,11 The magnitude
and timing of these effects are comparable to those reported
by other investigators using similar treatment protocols.45–48
Table 1 summarizes more detailed analyses of urine and
blood samples from animals treated with Cd for 6 weeks and
12 weeks. After 6 weeks, there were no changes in the urine or
blood parameters, except that blood urea nitrogen was
slightly elevated. After 12 weeks of exposure to Cd, however,
there were significant increases in urine volume, and urinary
levels of protein, lactate dehydrogenase and albumin. There
were also significant changes in urine pH, specific gravity,
and blood urea nitrogen. Urinary glucose and serum
creatinine also appeared to be elevated, although the changes
did not reach levels of statistical significance.
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Figure 1 | Effects of Cd on body weight, urine volume, urinary creatinine, and urinary protein. Male Sprague–Dawley rats received
daily subcutaneous injections of Cd (0.6 mg/kg) for up to 12 weeks, and one day each week, (a) animals were weighed, (b) 24-h urine samples
were collected and (c) analyzed for creatinine and (d) protein as described in the Materials and Methods section. Values represent the
mean7s.e.m. An * indicates significant differences from week matched control values as determined by two-way ANOVA (Po0.05) and
Tukey’s post hoc test. #Significant differences from week matched control values as determined by the non-parametric Kruskal–Wallis test
(Po0.05) and Dunn’s post hoc test for multiple comparisons; n¼ 10–17 for each data point.
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Excretion of Kim-1, CC-16, and metallothionein
As can be seen in Figure 2, elevated levels of Kim-1 appeared in
urine after 5–6 weeks of Cd exposure and then continued to
rise slightly over the next 2 weeks. Between weeks 8 and 9,
levels of Kim-1 increased markedly and remained elevated
throughout the remainder of the treatment period. The
excretion of both CC-16 and metallothionein followed similar
patterns, although significant increases in the excretion of
these molecules occurred later than the increase in Kim-1
excretion. Over the first 9 weeks, the urinary levels of both
molecules appeared to increase slowly, and then over the final
3 weeks the excretion of both proteins increased markedly.
The specific time at which the increases in the excretion of
these markers reached a level of statistical significance
(Po0.05) depended on the type of statistical analysis used.
Analysis of the data by standard parametric tests (analysis of
variance (ANOVA) and Tukey’s post hoc test), which are
similar to methods used in previous studies on these
biomarkers,17,34,36,42,49,50 showed that the increase in Kim-1
excretion reached a level of significance (Po0.05) after 9
weeks, whereas the increases in the excretion of CC-16 and
metallothionein did not reach levels of significance until 11
and 10 weeks respectively. This type of parametric analysis,
however, is not the most appropriate test for these data
because the variances are not homogenous (see Materials and
Methods). When the data were analyzed by the more
appropriate non-parametric Kruskal–Wallis test and Dunn’s
post hoc test, the increase in Kim-1 excretion reached a level
of statistical significance after 6 weeks, whereas the increase in
the excretion of CC-16 and metallothionein did not reach
levels of significance until 8 weeks and 12 weeks, respectively.
In considering these statistical analyses, it should be noted
that the levels of CC-16 in about 30% of the samples from
control animals were below levels of sensitivity of the assays
(which were 3 ng/ml and 1 ng/ml in the two assay runs). In
performing the statistical analyses, a numerical value half way
between 0 and the lowest detectable level was entered for
these samples. Since levels of CC-16 in most of the control
samples were well above the limit of sensitivity, entering
values as half the detection limit probably underestimated the
levels of CC-16 in the control samples and actually increased
the chances that Cd-induced elevations in urinary levels of
Table 1 | Summary of urine and blood analysis data for weeks 6 and 12 samples
6 Weeks 12 Weeks
Parameter Control Cd Control Cd
Urine volume (ml/kg/24 h) 34.372.2 47.375.0 18.871.5 148714*
Urinary protein (mg/kg/24 h) 48.473.5 55.173.4 41.175.1 117728*
Urinary creatinine (mg/kg/24 h) 27.571.6 24.572.4 28.771.7 30.271.2
Urinary glucose (mg/kg/24 h) 7.7870.81 7.9370.51 7.970.7 16.775.6
Urinary alkaline phosphatase (U/kg/24 h) 2.8470.57 3.6170.58 3.670.31 4.470.58
Urinary LDH (U/kg/24 h) 1.0570.030 0.6670.08 0.1570.02 4.070.7*
Urinary albumin (mg/kg/24 h) 0.5770.23 1.0870.31 0.8770.07 9.071.7*
Urine pH 8.4170.3 8.070.03 7.270.3 9.070*
Urine specific gravity 1.00670.003 1.00670.002 1.01070.002 1.00070*
Serum creatinine (mg/dl) 0.4570.05 0.4870.05 0.9270.03 1.370.16
BUN (mg/dl) 17.572.0 23.270.8* 27.671.8 43.072.8*
BUN, blood urea nitrogen; Cd, cadmium; LDH, lactate dehydrogenase.
Animals were treated with Cd (0.6 mg/kg, 5 days per week) for 6 or 12 weeks, and urine and blood samples were analyzed as described in the Materials and Methods section. The
results for most of the urine analyses represent the mean7s.e.m. of 10–11 replicate samples for each treatment group. The values for serum creatinine and BUN represent the
mean7s.e.m. for six controls and five Cd-treated animals. Since the Cd-treated animals gained significantly less weight than the control animals, the results of the urine analyses
are expressed as units per kg body weight per 24 h. An * denotes significant differences from week matched control values as determined by two-tailed t-tests (Po0.05).
*#
*#
*#
*#
*#
#
###
##
*#
*
*
*
Kim-1
Control
Cadmium
n
g/
kg
/2
4 
h

g/
kg
/2
4 
h

g/
kg
/2
4 
h
1500
1200
900
600
300
1200 Metallothionein
CC-16
1000
800
600
400
200
Week
1 2 3 4 5 6 7 8 9 10 11 12
35
18
21
14
7
Figure 2 | Effects of Cd on the urinary excretion of Kim-1, CC-16,
and metallothionein. Animals were treated with Cd (0.6 mg/kg, 5
days per week) for up to 12 weeks and weekly urine samples were
analyzed for levels of Kim-1, CC-16, and metallothionein as described
in the Materials and Methods section. Values represent the
mean7s.e.m. An * indicates significant difference from week
matched control values (Po0.05) as determined by two-way ANOVA
and Tukey’s post hoc test. #Significant difference from week matched
control values (Po0.05) as determined by the non-parametric
Kruskal–Wallis test and Dunn’s post hoc test for multiple comparisons.
For the Kim-1 data, n¼ 16–17 for weeks 1–6, and 10–11 for weeks
7–12; for CC-16, n¼ 10–11; and for metallothionein, n¼ 5.
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CC-16 would be statistically significant. The key point here is
that even with this bias, the results of each of these statistical
analyses indicate that the Cd-induced increase in Kim-1
excretion occurred before the increases in the excretion of
CC-16 and metallothionein.
Dose–response relationship
To determine if the Cd-induced increased in Kim-1 urinary
excretion was dependent on the dose of Cd, groups of rats
were treated with either 0, 0.6, 1.2, or 2.4 mg/kg Cd, 5 days
per week for 4 weeks. Figure 3 shows that after 4 weeks of
treatment, the higher doses of Cd (1.2 and 2.4 mg/kg) caused
significant increases in the excretion of Kim-1, and that the
magnitude of the increase was directly related to the dose of
Cd to which the animals were exposed. The data summarized
in Table 2 shows that the animals that were treated with the
higher doses of Cd (1.2 and 2.4 mg/kg/day) exhibited
significant weight loss along with increases in urine volume,
and urinary levels of protein and lactate dehydrogenase.
Blood urea nitrogen was also significantly elevated, but serum
creatinine was not, attesting to the insensitivity of serum
creatinine as a biomarker of nephrotoxicity.
Renal morphology and Kim-1 expression
Figure 4 shows hematoxylin and eosin-stained tissue sections
of outer renal cortex from control and Cd-treated (0.6 mg/kg/
5 days per week for 6 or 12 weeks) animals, along with the
immunoperoxidase labeling of Kim-1 in similar sections. The
hematoxylin and eosin-stained sections show that the major
site of Cd toxicity was the proximal tubule. Proximal tubule
epithelial cells in the control samples exhibited cuboidal
shapes, well-defined nuclei, and a uniform cytoplasm, with
no spaces or gaps between the cells. By contrast, the epithelial
cells in the samples from Cd-treated animals (top center and
top right) showed a ragged, irregular appearance, with gaps
between the cells. The cells remained attached to the
basement membrane, however, and showed no overt
evidence of necrosis. Analyses of the glomeruli and distal
segments of the nephron revealed no evidence of pathology
(not shown). The immunoperoxidase labeling shows that
after 6 weeks of Cd exposure, Kim-1 was present in a few cells
within isolated proximal tubules (arrows). After 12 weeks,
Kim-1 labeling was more widely distributed (arrows) in the
cytoplasm and on the apical surface of the epithelial cells in
about 25% of the proximal tubules. Figure 5 summarizes the
results of real-time reverse transcriptase-polymerase chain
reaction (RT-PCR) gene expression analyses in the renal
cortex. Kim-1 transcript levels in control samples were very
low. In samples from the Cd-treated animals, however, Kim-1
transcript levels were increased by six-fold at 6 weeks and by
24-fold at 12 weeks.
To determine if the Cd-induced changes in Kim-1
expression were associated with the death of epithelial cells
in the proximal tubule, kidneys from representative animals
were perfused in situ with the membrane impermeable
nuclear fluorochrome ethidium homodimer, and the number
of ethidium-labeled nuclei in cryosections of the outer cortex
was determined using a method recently developed in the
Prozialeck laboratory.51 As a positive control to identify
necrotic cells, three additional animals were treated acutely
with HgCl2 (3.5 mg Hg/kg, intraperitoneally), a treatment
that produces proximal tubule necrosis within 24 h.51 The
results of this study are summarized in Figure 6. The photos
in the top row show phase-contrast images of the micro-
scopic fields; those in the middle row show the 4,6
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Figure 3 | Dose dependence of the Cd-induced increase in Kim-1
excretion. Animals were treated with varying doses of Cd (0, 0.6, 1.2,
or 2.4 mg/kg/5 days per week for 4 weeks) and urine was analyzed for
levels of Kim-1 as described in the Materials and Methods section.
The results represent the mean7s.e.m. of six replicate samples for
each treatment group. An * denotes significant differences from
control values (Po0.05) as determined by the non-parametric
Kruskal–Wallis test and Dunn’s post hoc test.
Table 2 | Summary of urine and blood analyses for 4-week dose–response study
Parameter Control Cd (0.6 mg) Cd (1.2 mg) Cd (2.4 mg)
Body weight (g) 37276.4 34276.5* 324710* 30476.1*
Urine volume (ml/kg/24 h) 25.972.9 43.178.6 80.8715 209743*
Urinary protein (mg/kg/24 h) 57.275.8 77.9710 76.176.0 109717*
Urinary alkaline phosphatase (U/kg/24 h) 2.970.23 3.770.4 3.970.6 5.871.4
Urinary LDH (U/kg/24 h) 1.370.1 1.770.1 4.670.3* 19.071.7*
Serum creatinine (mg/dl) 0.6070.1 0.5070.0 0.5870.05 0.5470.04
BUN (mg/dl) 21.773.0 19.570.9 22.572.8 31.671.7*
BUN, blood urea nitrogen; Cd, cadmium; LDH, lactate dehydrogenase.
Animals were treated with varying doses of Cd (0, 0.6, 1.2, or 2.4 mg/kg/5days per week for 4 weeks) and urine and blood samples were analyzed as described in the Materials
and Methods section. The results represent the mean7s.e.m. of 5–6 replicate samples for each treatment group. Since the Cd-treated animals gained significantly less weight
than the control animals, the results of the urine analyses are expressed as units per kg body weight per 24 h. An * denotes significant differences from control values as
determined by ANOVA and post hoc Tukey’s test (Po0.05).
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diamidino-2 phenylindole (DAPI)-labeled nuclei (total cells)
in the same fields and those in the bottom row show the
ethidium labeling (necrotic cells). Note that the number of
ethidium-labeled nuclei in samples from the Cd-treated
animals was not significantly different from controls, whereas
the number of ethidium-labeled nuclei in samples from the
Hg-treated animals was much higher. The fact that the
samples from the Cd-treated animals showed no apparent
increase in the number of ethidium-labeled cells indicates
that the vast majority of proximal tubule epithelial cells were
still viable, and that the changes in Kim-1 expression did not
occur secondary to necrosis.
DISCUSSION
The results of these studies utilizing a well-established model
of sub-chronic Cd exposure in rats indicate that Kim-1 is a
sensitive marker of Cd-induced proximal tubular injury.
Significantly elevated levels of Kim-1 appeared in the urine
after 6 weeks of treatment with Cd, whereas overt polyuria
and proteinuria, which are classic signs of Cd-induced
proximal tubule injury, did not become evident until 9–10
weeks of Cd treatment. Immunohistochemical analyses
showed that Kim-1 was expressed in the epithelial cells of
the proximal tubule. Additional studies showed that the
magnitude of the increase in the urinary excretion of Kim-1
was directly related to the dose of Cd to which the animals
were exposed.
To further evaluate the possible utility of Kim-1 as an early
marker of Cd-induced proximal tubular injury, we directly
compared the time course for the appearance of Kim-1 in
urine with the appearance of metallothionein and CC-16,
which are two widely accepted markers of Cd nephrotoxicity.
Slightly elevated levels of all three markers began to appear in
the urine very early in the course of treatment (i.e., after 2–3
weeks) and continued to rise in a more or less linear manner
over the next 5–6 weeks, at which point there was a
pronounced increase in the excretion of all three markers.
The specific time points at which the increases in the
excretion of the markers reached levels of statistical
significance varied depending on the type of statistical
analysis performed. However, the results consistently showed
that the Cd-induced increase in the excretion of Kim-1
preceded the increases in the excretion of metallothionein
and CC-16 by 1–3 weeks.
In comparing Kim-1, metallothionein, CC-16, and b2-
microglobulin as markers of nephrotoxicity, it is important
to note that each of these molecules is derived from different
sources and their appearance in the urine is indicative of
different events in the process of Cd nephrotoxicity. For
example, the Cd–metallothionein complex is initially formed
in the liver and redistributes to the kidney, where it is filtered
at the glomerulus.24,52–54 While most of the filtered
Cd–metallothionein complex is efficiently taken up by
epithelial cells of the proximal tubule, small amounts are
also excreted in urine. During this phase, the appearance of
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Kim-1, Control Kim-1, Cd 6 weeks Kim-1, Cd 12 weeks
100 m
H+E, Cd 6 weeks H+E, Cd 12 weeks
Figure 4 | Effects of Cd on the general morphology and the expression of Kim-1 in renal cortex. Rats were treated with Cd (0.6 mg/
kg/5 days per week) for 6 or 12 weeks, and representative sections of the renal cortex were processed for hematoxylin and eosin staining
and the visualization of Kim-1 (original magnification 164).
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Figure 5 | Real time RT-PCR analysis of Kim-1 expression.
Total RNA was isolated from the renal cortex and subjected to real
time RT-PCR analysis as described in the Materials and Methods
section (n¼ 4 for the 6-week controls and 6 for all other treatment
groups). An * denotes significant differences from week matched
control values as determined by two-tailed t-tests (Po0.05).
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metallothionein in urine is mainly an indication of Cd
exposure, rather than tubular injury.35 With continued
exposure, Cd–metallothionein is taken up by the proximal
tubule until the concentration of Cd reaches a critical
threshold.27,55–57 At this point, the cells begin to die and
slough off into the urine. During this phase, the levels of
urinary metallothionein increase markedly and are indicative
of injury to the proximal tubule.35 Our results show that
metallothionein begins to appear in the urine after 1–2 weeks
of exposure to Cd. The levels then slowly rise until weeks
9–10, at which point there is a marked increase in the urinary
excretion of metallothionein. This surge in the urinary
excretion of metallothionein coincides with the onset of
polyuria and proteinuria. This pattern is similar to that
reported by other investigators19,28,33,36,58 and is consistent
with the hypothesis that the early, linear phase of metal-
lothionein excretion is a reflection of Cd exposure, whereas
the later rise in metallothionein excretion is a reflection of
Cd-induced tubular injury.
CC-16 is primarily produced by Clara cells of the lung.59,60
It is normally present at low levels in plasma from where it is
filtered at the glomerulus and efficiently reabsorbed by the
proximal tubule.29,60 Significant amounts of the protein
appear in the urine, however, when the proximal tubule is
injured.23,61 While CC-16 has been reported to be a sensitive
maker of Cd-induced renal dysfunction in humans23 and
rats,34 the appearance of CC-16 in urine is not necessarily a
specific marker of renal injury. Urinary levels of CC-16 may
also reflect increases in serum levels of the protein resulting
from pathologic processes occurring in the lung. For
example, serum levels of CC-16 are increased by exposure
to pneumotoxins such as cigarette smoke,61,62 nitric oxide,63
and ozone.29,49 The fact that CC-16 is not a specific marker of
renal injury could complicate the interpretation of studies
involving a toxic substance such as Cd that can affect
multiple organs such as the lung and kidney. Like CC-16, b2-
microglobulin is also not necessarily a specific marker of
proximal tubular injury. As the invariant light-chain
component of class I major histocompatibility antigens,64
b2 microglobulin is derived from many tissues and serum
levels of the protein can be influenced by pathologic
processes in a variety of organs.63,65–68 The fact that Kim-1
is specifically produced by injured epithelial cells of the
proximal tubule and then shed into urine suggests that it may
be a more specific marker of Cd-induced proximal tubular
injury.
Although these studies indicate that Kim-1 is a very early
biomarker of Cd nephrotoxicity, the specific relationships
between the expression of Kim-1 and the pathophysiologic
events of Cd-induced renal injury are not yet totally clear.
Evidence suggests that Kim-1 is expressed as part of the tissue
repair process after injured cells slough off from the proximal
tubule and surviving cells migrate to the denuded areas of the
basement membrane to reform the epithelial barrier.40 A key
issue that is yet to be resolved, however, concerns the nature
of the initial Cd-induced cellular injury that triggers this
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Control ethidium Cd ethidium (6 weeks) Cd ethidium (12 weeks) Hg ethidium
Cd DAPI (6 weeks) Cd DAPI (12 weeks) Hg DAPI
Cd (6 weeks) Cd (12 weeks) Hgb c da
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Figure 6 | The effects of Cd and Hg on renal cell membrane integrity. Animals were treated with either Cd (0.6 mg/kg, subcutaneously
5 days a week for 6 weeks) or HgCl2 (3.5 mg/kg of Hg, intraperitoneally), and the left kidneys were perfused with ethidium homodimer.
Cryosections of the kidneys were then fixed, permeabilized, and labeled with DAPI to identify total nuclei. (a–d) Phase-contrast images
corresponding to DAPI-labeled panels (e–h) and ethidium homodimer-labeled panels (i–l). No differences in ethidium homodimer labeling were
detected in (j) 6-week Cd2þ -treated samples or (k) 12-week Cd-treated samples compared with (i)12 week saline-treated control. In contrast,
samples from Hg-treated animals showed widespread necrosis (l), as indicated by intense ethidium labeling (original magnification 164).
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response. One possibility is that the injured cells die, either
through necrotic or apoptotic mechanisms, and then slough
off with resultant Kim-1 appearance in the urine. The other
possibility is that sublethal cellular injury might lead to a
loss of epithelial cell–cell adhesion and cause some cells to
detach from the epithelial surface. The results of this study
showed that there was little evidence of necrosis of proximal
tubule epithelial cells at the time Kim-1 began to appear in
urine. This finding is consistent with recent observations
that the early stages of Cd nephrotoxicity involve changes in
proximal tubule function that occur before overt necrosis of
epithelial cells.69 Other studies indicate that these early
stages of Cd-induced renal injury involve alterations in
epithelial cell–cell adhesion and epithelial polarity,69,70 and
are associated with changes in the localization of cell
adhesion molecules such as N-cadherin69 and claudin-2.71
Together, these findings suggest that the disruption of cell
adhesion molecule function may represent a critical step in
the process of Cd-induced renal injury, and in the activation
of Kim-1 expression. Additional studies are needed,
however, to clarify this issue.
Another potential benefit of Kim-1 as a biomarker for Cd-
induced renal injury is that it is conserved across species and
is upregulated after renal injury in a variety of species
including mice,72 rats,39 non-human primates,73 and
humans.74 While it remains to be determined if Kim-1
excretion is increased in humans who have been exposed to
Cd, the availability of a standard marker that is conserved
across species could greatly facilitate the extrapolation of the
results of studies in animals to the results of studies on
human populations and vice versa.
MATERIALS AND METHODS
Animals
Male Sprague–Dawley rats weighing 250–300 g (Harlan, Indianapo-
lis, IN, USA) were maintained in individual plastic cages on a
14/10 h light/dark cycle. For the low-dose, sub-chronic studies, animals
in the Cd treatment group (n¼ 6) received daily (Monday–Friday)
subcutaneous injections of CdCl2 at a Cd dose of 0.6 mg
(5.36mmoles)/kg in 0.25–0.40 ml isotonic saline for up to 12 weeks.
Control group animals (n¼ 6) received daily injections of the saline
vehicle alone. One day each week, 24 h urine samples were collected.
The animals were allowed free access to water at all times. Food was
also available ad libitum, except during the period in which the urine
samples were being collected. This treatment protocol was repeated
three times and data were pooled whenever possible. In another
study, groups of animals were treated with varying doses of Cd (0,
0.6, 1.2, or 2.4 mg/kg/) 5 days per week for 4 weeks.
Urine and blood analyses
Twenty-four-hour urine samples were analyzed for protein and
creatinine content. Sample aliquots were immediately frozen at
801C and then later analyzed for levels of Kim-1, CC-16, and
metallothionein. Creatinine was determined by the colorimetric
method of Shoucri and Pouliot.75 Urinary protein was determined
by the Bradford Coomassie blue dye assay (Pierce no. 23236,
Rockford, IL, USA). Glucose, pH and specific gravity, alkaline
phosphatase, lactate dehydrogenase, blood urea nitrogen, and serum
creatinine were analyzed at the Animal Resources Laboratory at the
University of Chicago.
Determination of Kim-1, metallothionein, and CC-16
Urine samples were coded so that individuals performing the
analyses were blinded as to the identity of the samples. Kim-1
protein was measured using Microsphere-based Luminex xMAPTM
technology with monoclonal antibodies raised against rat Kim-1 in
the Vaidya/Bonventre laboratory. This technique is an adaptation of
the recently developed and validated sandwich enzyme-linked
immunosorbant assay, that was described at the 2005 American
Society of Nephrology Meeting (Vaidya et al., J Am Soc Nephrol
16:192A, 2005, abstract). This assay has been extensively evaluated
with respect to its assay range (4–40 000 pg/ml), sensitivity (lowest
limit of detection: 8.8 pg/ml), specificity, recovery analysis (90–100%
recovery) precision profile (inter and intra assay variability o10%),
and dilutional linearity. The validation studies also showed
a significant correlation of 92% between enzyme-linked immuno-
sorbant assay and this microbead-based assay. This assay has been
used to determine urinary levels of Kim-1 in several recent studies
on rats.42,44,76,77 Urinary metallothionein levels were determined by
an enzyme-linked immunosorbant assay procedure28,78 in the Liu/
Waalkes laboratory. Levels of CC-16 were determined in the
Dumont/Bernard laboratory using an automated immunoassay
based on latex particle agglutination and an antibody specific for
rat CC-16.34,79
Immunohistochemical visualization of Kim-1
Formalin-fixed, paraffin-embedded tissue sections (5mm) were
deparaffinized in xylene, rehydrated with a series of alcohol washes,
and then incubated for 20 min at 951C in a citrate buffer solution
(Zymed Laboratories, #00–5000, South San Francisco, CA, USA).
The samples were then processed for visualization of Kim-1 using a
monoclonal anti-rat Kim-1 antibody and the same labeling protocol
for paraffin embedded tissue samples described previously.80
Real-time RT-PCR analysis of Kim-1 expression
RNA was isolated from samples of renal cortex with TRIzol reagent
(Invitrogen, Carlsbad, CA, USA), and purified with RNeasy mini-kit
(Qiagen, Valencia, CA, USA). Primers for the Kim-1 gene
(NM_173149: forward primer: TGGCACTGTGACATCCTCAGA,
reverse primer: GCAACGGACATGCCAACATA) and the house-
keeping GAPDH gene (NM_017008: forward primer: CCTGGAGAA
ACCTGCCAAGTAT, reverse primer: AGCCCAGGATGCCCTTT
AGT) were designed using ABI Primer Express software (Applied
Biosystems, Foster City, CA, USA). Total RNA was reverse
transcribed with ABI High-Capacity cDNA Reverse Transcription
kit and then subjected to real-time PCR using ABI SYBR green PCR
master mix (Applied Biosystems, Cheshire, UK). The cycle time
values of Kim-1 were normalized with GAPDH, and the relative
differences between control and Cd groups were calculated and
expressed as percentage of controls.
Evaluation of proximal tubule epithelial cell necrosis
Necrosis of proximal tubule epithelial cells was evaluated by
perfusing the left kidney with the cell viability indicator, ethidium
homodimer, using a procedure recently developed and validated in
the Prozialeck laboratory.51 Following the perfusion procedure, the
left kidney was removed and cryosectioned at a thickness of 5 mm.
Sections were mounted on glass slides, fixed, permeabilized in
201C methanol, and stained with 0.3 mM DAPI, to label all nuclei.
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Fields were viewed under both phase-contrast and fluorescent
illumination using a  40 objective The number of total nuclei
(DAPI labeled) and dead cells (ethidium-labeled nuclei) were
determined in random fields of renal cortex. Each field contained
approximately 300 cells in an area of 9.1 104mm2. Digital images
were captured with a Spot digital camera (Diagnostic Instruments,
Sterling Heights, MI, USA) and processed using the Image-Pro Plus
imaging analysis software package (Media Cybernetics, Silver
Spring, MD, USA).51
Statistical analysis
Statistical analyses were performed using the Sigma Stat computer
program (Version V2.03, Systat Software Inc., Point Richmond, CA,
USA). Data for the various urinary parameters were evaluated by
two different types of analyses. The first approach involved the use
of standard ANOVA, followed by post hoc Tukey’s tests to determine
differences among the various treatment groups. This was done
because similar tests have been commonly used in many previous
studies on the urinary excretion of these markers in similar
models.34,36,42,49,50,81 However, while performing these analyses, we
found that this approach might not be appropriate, because the data
points for the later treatment periods showed significantly more
variability than the points for earlier treatment periods. ANOVA and
Tukey’s tests are parametric tests that assume normality of
distribution and homogeneity of variances (i.e., that standard
deviations are equal for all treatment groups).82 Analysis of the
present data by the Kolmogorov–Smirnov test (normality) and
Levene’s test (homogeneity of variances) showed that much of the
data did not meet these criteria. Accordingly, the data were also
analyzed by the non-parametric Kruskal–Wallis test and Dunn’s
post hoc test for multiple comparisons, which are more appropriate for
these types of variable, heterogeneous data.82 Since many previous
studies on these markers utilized parametric methods, we have
included the results of both our parametric and non-parametric
analysis so that the reader can directly compare the results of this
study with those previously reported in the literature.
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